|
Volumn 15, Issue 5, 2010, Pages 282-283
|
The perfect storm: CNS drug development in trouble
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIDEPRESSANT AGENT;
CENTRAL NERVOUS SYSTEM AGENTS;
LAMOTRIGINE;
LITHIUM SALT;
NEUROLEPTIC AGENT;
NEW DRUG;
QUETIAPINE;
BIPOLAR DISORDER;
BUDGET;
CLINICAL EFFECTIVENESS;
CLINICAL RESEARCH;
COMBINATION CHEMOTHERAPY;
COST;
DEPRESSION;
DRUG INDUSTRY;
DRUG MANUFACTURE;
EDITORIAL;
FUNDING;
HEALTH CARE POLICY;
INVESTMENT;
MONOTHERAPY;
PERFORMANCE MEASUREMENT SYSTEM;
PRIORITY JOURNAL;
PROFIT;
|
EID: 77952571701
PISSN: 10928529
EISSN: None
Source Type: Journal
DOI: 10.1017/S1092852900027486 Document Type: Editorial |
Times cited : (14)
|
References (6)
|